Abstract
Angiogenesis during reactive and pathologic processes is characteristically associated with inflammation. Macrophages and dendritic cells present in the inflammatory infiltrate contribute to the angiogenic process by multiple mechanisms. Macrophages produce a broad array of angiogenic growth factors and cytokines, generate conduits for blood flow through proteolytic mechanisms, and promote the remodeling of arterioles into arteries. They can also inhibit angiogenesis and cause reabsorption of neovessels by inducing endothelial cell death. Dendritic cells can stimulate or inhibit angiogenesis depending on their activation status and subset specificity. Dendritic cells stimulate angiogenesis by secreting angiogenic factors and cytokines, promoting the proangiogenic activity of T lymphocytes, and trans-differentiating into endothelial cells. Inflammatory infiltrates associated with angiogenesis also contain Tie2+, VEGFR2+, and GR1+ myelomonocytic cells which actively regulate the angiogenic process through paracrine mechanisms. In this paper we review our current knowledge of this field and discuss how recent advances have provided the rationale for novel therapeutic approaches against cancer.
Keywords: Macrophages, dendritic cells, myeloid cells, neovascularization, arteriogenesis
Current Pharmaceutical Design
Title: Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Volume: 15 Issue: 4
Author(s): Zhao Ming (David) Dong, Alfred C. Aplin and Roberto F. Nicosia
Affiliation:
Keywords: Macrophages, dendritic cells, myeloid cells, neovascularization, arteriogenesis
Abstract: Angiogenesis during reactive and pathologic processes is characteristically associated with inflammation. Macrophages and dendritic cells present in the inflammatory infiltrate contribute to the angiogenic process by multiple mechanisms. Macrophages produce a broad array of angiogenic growth factors and cytokines, generate conduits for blood flow through proteolytic mechanisms, and promote the remodeling of arterioles into arteries. They can also inhibit angiogenesis and cause reabsorption of neovessels by inducing endothelial cell death. Dendritic cells can stimulate or inhibit angiogenesis depending on their activation status and subset specificity. Dendritic cells stimulate angiogenesis by secreting angiogenic factors and cytokines, promoting the proangiogenic activity of T lymphocytes, and trans-differentiating into endothelial cells. Inflammatory infiltrates associated with angiogenesis also contain Tie2+, VEGFR2+, and GR1+ myelomonocytic cells which actively regulate the angiogenic process through paracrine mechanisms. In this paper we review our current knowledge of this field and discuss how recent advances have provided the rationale for novel therapeutic approaches against cancer.
Export Options
About this article
Cite this article as:
(David) Dong Ming Zhao, Aplin C. Alfred and Nicosia F. Roberto, Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells, Current Pharmaceutical Design 2009; 15 (4) . https://dx.doi.org/10.2174/138161209787315783
DOI https://dx.doi.org/10.2174/138161209787315783 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Alcoholic Bark Extract of <i>Terminalia Arjuna</i> Exhibits Cytotoxic and Cytostatic Activity on Jurkat Leukemia Cells
Venoms and Toxins Analysis of Adverse Events Related to 720 Cases of Neural Progenitor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Evaluation of Melatonin Effect on Human Breast Cancer Stem Cells Using a Threedimensional Growth Method of Mammospheres
Anti-Cancer Agents in Medicinal Chemistry EDITORIAL (Hot Topic: Cancer Chemoresistance and DNA Repair)
Current Medicinal Chemistry Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Salen Mn Complexes Mitigate Radiation Injury in Normal Tissues
Anti-Cancer Agents in Medicinal Chemistry CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Pioglitazone Prevents Smoking Carcinogen-Induced Lung Tumor Development in Mice
Current Cancer Drug Targets Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy
Current Cancer Drug Targets Medicinal Chemistry of 5-HT5A Receptor Ligands: A Receptor Subtype with Unique Therapeutical Potential
Current Topics in Medicinal Chemistry Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Current Gene Therapy Synergistic Interplay of Medicinal Chemistry and Formulation Strategies in Nanotechnology – From Drug Discovery to Nanocarrier Design and Development
Current Topics in Medicinal Chemistry Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design